Foldable IOL for glaucoma requires long-term follow-up

Article

Long-term follow-up is necessary in secondary pigmentary glaucoma patients implanted with a foldable IOL in the ciliary sulcus, advises a recent journal paper.

Long-term follow-up is necessary in secondary pigmentary glaucoma patients implanted with a foldable IOL in the ciliary sulcus, advises a recent journal paper.

A team led by Dr Shirley H. L. Chang, Department of Ophthalmology, Chang Gung Memorial Hospital, Chang Gung University, Taiwan, retrospectively reviewed 10 eyes of 10 patients who developed secondary pigmentary glaucoma after cataract operations. Results were based on data collected on cases between 2002 and 2011. Each patient underwent foldable IOL implantation in the ciliary sulcus.

IOP elevation was seen in 2 eyes within the first 2 weeks after cataract surgery and the onset of glaucoma was delayed in the remaining 8 eyes. The average onset time for the 8 eyes was 21.9 ± 17.1 months after the initial cataract operation.

Surgical treatment was administed to six eyes due to large IOP fluctuations and poor IOP control. Of the total eyes studied, only 3 presented with final visual acuities exceeding 20/40.

The visual prognosis for patients with secondary pigmentary glaucoma can be poor and implanting a foldable IOL in the ciliary sulcus could threaten vision. The study group advise that the long-term follow-up of IOP in these patients is required.

To read the abstract please visit BMC Ophthalmology.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
© 2025 MJH Life Sciences

All rights reserved.